Huge strides have been made in diagnosing and treating childhood cancers, but most of those benefits are seen in the wealthiest countries in the world. This leaves hundreds of thousands of children in need of adequate cancer care. Dr. André Ilbawi with the World Health Organization tells us about their initiative that aims to bridge this gap, and deliver services to children in low and middle resourced countries with the goal of saving one million children by 2030.

Bladder cancer used to be a disease with very few effective treatment options. That was until two new strategies came on the scene: immunotherapies and antibody drug conjugates. These approaches have changed the way doctors treat bladder cancer, and prolonged the lives of many patients. Dr. Tom Powles, head of Barts Cancer Institute, tells Chuck and Alicia about his work on developing these treatments and where he hopes science will take us next.

Radioligand therapy is a form of precise cancer treatment that targets specific cells with a radioactive substance. It’s used to treat prostate cancer and some types of neuroendocrine cancer, delivering powerful results with minimal impact on patient quality of life. Dr. Michael Morris helped develop radioligands for prostate cancer, and he tells Chuck and Alicia about the huge promise he sees in these treatments going forward.